Liver Cancer Trial, Recruiting NCT04556214 Sponsor: Oslo University Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT04556214
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been confirmed through a tissue biopsy to have a specific type of liver cancer called intrahepatic cholangiocarcinoma (iCCA)
  • This is either your first time being diagnosed with iCCA, or the cancer has come back only in the liver after a previous liver surgery
  • Doctors have decided that surgery to remove part of your liver is not possible, due to where the tumor is located or because your liver is not healthy enough
  • Scans have shown no signs that the cancer has spread into nearby blood vessels, outside the liver, or into lymph nodes
  • A special full-body scan (PET-CT) has shown no signs of cancer spread outside the liver
  • You have been accepted as a candidate for a liver transplant before your cancer got worse while on chemotherapy
  • At least 12 months have passed between your iCCA diagnosis and the date you are placed on the liver transplant waiting list
  • A CT or MRI scan done within the 4 weeks before your assessment at the transplant centre shows no signs of cancer outside the liver
  • You are 18 years of age or older
  • You are in good general health and are able to carry out everyday activities with little or no difficulty (confirm with trial site)
  • You are willing to give your formal consent and are able to attend appointments for treatment and follow-up
  • You have already received at least 6 months of chemotherapy or a local treatment directed at the liver tumour

Who may not be able to join:

  • The cancer has grown into major blood vessels near the liver
  • There has been a rupture or tear in the lining surrounding the abdominal organs
  • You have lost more than 15% of your body weight in the last 6 months
  • Your Body Mass Index (BMI) is over 30
  • You have or have had another type of cancer, unless it was fully treated more than 5 years ago and has not come back
  • You have a known history of HIV infection
  • You have previously had a transplant of a solid organ or bone marrow
  • You have substance use issues, or medical, mental health, or social circumstances that could affect your ability to take part in the trial (confirm with trial site)
  • You have a known allergy or sensitivity to a medication called rapamycin
  • Your cancer has previously spread to areas outside the liver
  • You are currently pregnant or breastfeeding
  • The trial doctor has any other concern that makes participation unsuitable for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Magnus Smedman, MD, Oslo University Hospital

Phone: 23026600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2020
Est. completion
31 May 2035

Where this trial is recruiting

🇳🇴 Norway

Primary endpoints

Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov